Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) has announced that its management will participate in two upcoming investor conferences. The company will join the Jefferies Global Healthcare Conference for a fireside chat on June 6 at 10:30 a.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference for a fireside chat on June 12 at 3:20 p.m. ET. These events will be live-streamed and archived on Avadel's Investor Relations website for 90 days post-conference.

Positive

• Participation in high-profile investor conferences can increase visibility and investor interest.
• Live webcasts and archived recordings provide ongoing access to company information for investors.

Negative

• There are no new financial or clinical data disclosed in the announcement.
• The announcement does not provide any detailed updates on business development or pipeline progress.
• Lack of specific milestones or targets may not spark significant investor enthusiasm.

DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:

• Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET.
• Goldman Sachs 45^th Annual Global Healthcare Conference: Fireside chat on Wednesday, June 12 at 3:20 p.m. ET.

A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687

Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162

FAQ

When will Avadel Pharmaceuticals present at the Jefferies Global Healthcare Conference?

Avadel Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 6 at 10:30 a.m. ET.

What time is Avadel Pharmaceuticals' fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference?

The fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference is on June 12 at 3:20 p.m. ET.

Where can I watch Avadel Pharmaceuticals' investor conferences?

You can watch the live webcasts and archived recordings on Avadel's Investor Relations website.

How long will the recordings of Avadel Pharmaceuticals' investor conferences be available?

The recordings will be available for 90 days following each conference.